Strategies for achieving transfusion independence in myelodysplastic syndromes

European Journal of Oncology Nursing

Volumn 11, Issue 2, 2007, Pages 151-158

  Thomas, Mary Laudon ^a  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

Anemia; Iron overload; Myelodysplastic syndromes; Quality of life; Transfusions; Treatment

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE; DRUG DERIVATIVE; ERYTHROPOIETIN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; THALIDOMIDE;

ANEMIA; ARTICLE; DRUG COST; ECONOMICS; ERYTHROCYTE TRANSFUSION; HEALTH SERVICE; HUMAN; INFORMED CONSENT; MYELODYSPLASTIC SYNDROME; NURSE ATTITUDE; ONCOLOGY NURSING; ORGANIZATION AND MANAGEMENT; PATIENT EDUCATION; PATIENT SELECTION; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; TREATMENT OUTCOME;

ANEMIA; ANTILYMPHOCYTE SERUM; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DRUG COSTS; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFORMED CONSENT; MYELODYSPLASTIC SYNDROMES; NURSE'S ROLE; ONCOLOGIC NURSING; PATIENT EDUCATION; PATIENT SELECTION; QUALITY OF LIFE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 33947132677     PISSN: 14623889     EISSN: 15322122     Source Type: Journal    
DOI: 10.1016/j.ejon.2006.06.004     Document Type: Article

References (57)

1. Aplastic Anemia and MDS International Foundation, Inc., 2005. Myelodysplastic syndromes: basic explanations. 〈http://www.aamds-international.org/pdfs/myelodysbasic.pdf〉. Accessed: 8-16-2005.
2. Aul C., Germing U., Gattermann N., and Minning H. Increasing incidence of myelodysplastic syndromes: real or fictitious?. Leukemia Research 22 1 (1998) 93-100
3. Bartlett J.B., Dredge K., and Dalgleish A.G. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nature Reviews Cancer 4 4 (2004) 314-322
4. Bevans M.F., and Shalabi R.A. Management of patients receiving antithymocyte globulin for aplastic anemia and myelodysplastic syndrome. Clinical Journal of Oncology Nursing 8 4 (2004) 377-382
5. Bowen D., Culligan D., Jowitt S., Kelsey S., Mufti G., Oscier D., and Parker J. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. British Journal of Haematology 120 2 (2003) 187-200
6. Brittenham G.M., Griffith P.M., Nienhuis A.W., McLaren C.E., Young N.S., Tucker E.E., Allen C.J., Farrell D.E., and Harris J.W. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. New England Journal of Medicine 331 9 (1994) 567-573
7. Cappellini M.D. Iron-chelating therapy with the new oral agent ICL670 (Exjade). Best Practice and Research. Clinical Haematology 18 2 (2005) 289-298
8. Casadevall N., Durieux P., Dubois S., Hemery F., Lepage E., Quarré M.-C., Damaj G., Giraudier S., Guerci A., Laurent G., Dombret H., Chomienne C., Ribrag V., Stamatoullas A., Marie J.-P., Vekhoff A., Maloisel F., Navarro R., Dreyfus F., and Fenaux P. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 104 (2004) 321-327
9. Cazzola M., Anderson J.E., Ganser A., and Hellström-Lindberg E. A patient-oriented approach to treatment of myelodysplastic syndromes. Haematologica 83 10 (1998) 910-935
10. Cazzola M., and Malcovati L. Myelodysplastic syndromes-coping with ineffective hematopoiesis. New England Journal of Medicine 352 6 (2005) 536-538
11. Centers for Medicare and Medicaid Services, 2005. Median Costs for Drugs, Biologicals, and Radiopharmaceuticals and Median Costs for Hospital Outpatient Services by HCPCS Code. 〈http://www.cms.hhs.gov/providers/hopps/2005fc/1427fc.asp〉. Accessed: 8-4-2005.
12. Cheson B.D., Bennett J.M., Kantarjian H., Pinto A., Schiffer C.A., Nimer S.D., Löwenberg B., Beran M., de Witte T.M., Stone R.M., Mittelman M., Sanz G.F., Wijermans P.W., Gore S., and Greenberg P.L. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96 12 (2000) 3671-3674
13. Cremieux P.-Y., Barrett B., Anderson K., and Slavin M.B. Cost of outpatient blood transfusion in cancer patients. Journal of Clinical Oncology 18 14 (2000) 2755-2761
14. Demakos E.P., and Linebaugh J.A. Advances in myelodysplastic syndrome: nursing implications of azacitidine. Clinical Journal of Oncology Nursing 9 4 (2005) 417-423
15. Demetri G.D. Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. British Journal of Cancer 84 suppl 1 (2001) 31-37
16. Faderl S., and Kantarjian H.M. Novel therapies for myelodysplastic syndromes. Cancer 101 2 (2004) 226-241
17. Fenaux P. Myelodysplastic syndromes: from pathogenesis and prognosis to treatment. Seminars in Hematology 41 2 suppl 4 (2004) 6-12
18. Fitzgerald M., Hodgkinson B., and Thorp D. Blood transfusion from the recipient's perspective. Journal of Clinical Nursing 8 5 (1999) 593-600
19. Franchini M., and Veneri D. Iron-chelation therapy: an update. The Hematology Journal 5 4 (2004) 287-292
20. Giagounidis A.A.N., Germing U., Strupp C., Hildebrandt B., Heinsch M., and Aul C. Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. Annals of Hematology 84 9 (2005) 569-571
21. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., Sanz M., Vallespi T., Hamblin T., Oscier D., Ohyashiki K., Toyama K., Aul C., Mufti G., and Bennett J. International scoring system for evaluating prognosis in myelodysplastic syndromes (erratum appears in Blood 1998;91:1100). Blood 89 6 (1997) 2079-2088
22. Gupta P., LeRoy S.C., Luikart S.D., Bateman A., and Morrison V.A. Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications. Leukemia Research 23 10 (1999) 953-959
23. Hardy J.-F. Current status of transfusion triggers for red blood cell concentrates. Transfusion and Apheresis Science 31 1 (2004) 55-66
24. Hellström-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. British Journal of Haematology 89 1 (1995) 67-71
25. Hellström-Lindberg E. Treatment of adult myelodysplastic syndromes. International Journal of Hematology 70 3 (1999) 141-154
26. Hellström-Lindberg E. Approach to anemia associated with myelodysplastic syndromes. Current Hematology Reports 2 2 (2003) 122-129
27. Hellström-Lindberg E., Gulbrandsen N., Lindberg G., Ahlgren T., Dahl I.M.S., Dybedal I., Grimfors G., Hesse-Sundin E., Hjorth M., Kanter-Lewensohn L., Linder O., Luthman M., Löfvenberg E., Öberg G., Porwit-MacDonald A., Rådlund A., Samuelsson J., Tangen J.M., Winquist I., and Wisloff F. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin+granulocyte colony-stimulating factor: significant effects on quality of life. British Journal of Haematology 120 6 (2003) 1037-1046
28. Hofmann W.-K., Lübbert M., Hoelzer D., and Koeffler H.P. Myelodysplastic syndromes. The Hematology Journal 5 1 (2004) 1-8
29. Jansen A.J.G., Essink-Bot M.-L., Beckers E.A.M., Hop W.C.J., Schipperus M.R., and Van Rhenen D.J. Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. British Journal of Haematology 121 2 (2003) 270-274
30. Kaminskas E., Farrell A., Abraham S., Baird A., Hsieh L.-S., Lee S.-L., Leighton J.K., Patel H., Rahman A., Sridhara R., Wang Y.-C., and Pazdur R. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clinical Cancer Research 11 10 (2005) 3604-3608
31. 2/course) in myelodysplastic syndrome (MDS). Comparison of 3 different dose schedules (abstract no. 2522). Blood 106 part 1 (2005) 708a (abstract)
32. Kantarjian H., Issa J.P., Rosenfeld C.S., Bennett J.M., Albitar M., DiPersio J., Klimek V., Slack J., de Castro C., Ravandi F., Helmer R., Shen L., Nimer S.D., Leavitt R., Raza A., and Saba H. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106 8 (2006) 1794-1803
33. Killick S.B., Mufti G., Cavenagh J.D., Mijovic A., Peacock J.L., Gordon-Smith E.C., Bowen D.T., and Marsh J.C.W. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. British Journal of Haematology 120 4 (2003) 679-684
34. Kornblith A.B., Herndon J.E., Silverman L.R., Demakos E.P., Odchimar-Reissig R., Holland J.F., Powell B.L., DeCastro C., Ellerton J., Larson R.A., Schiffer C.A., and Holland J.C. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. Journal of Clinical Oncology 20 10 (2002) 2441-2452
35. Liesveld J.L., Jordan C.T., and Phillips G.L. The hematopoietic stem cell in myelodysplasia. Stem Cells 22 4 (2004) 590-599
36. List A.F. New approaches to the treatment of myelodysplasia. The Oncologist 7 suppl 1 (2002) 39-49
37. List A., Kurtin S., Roe D.J., Buresh A., Mahadevan D., Fuchs D., Rimsza L., Heaton R., Knight R., and Zeldis J..B. Efficacy of lenalidomide in myelodysplastic syndromes. New England Journal of Medicine 352 6 (2005) 549-557
38. List, A.F., Vardiman, J., Issa, J.-P., Dewitte, T.M., 2004. Myelodysplastic syndromes. Hematology (Am Soc Hematol Educ Program), pp. 297-317.
39. Mannone L., Gardin C., Quarre M.C., Bernard J.F., Giraudier S., and Rosenthal E. High response rate to darbopoietin alfa in "low risk" MDS: results of phase II study (abstract 69). Blood 104 part 1 (2004) 24a (abstract)
40. Molldrem J.J., Leifer E., Bahceci E., Saunthararajah Y., Rivera M., Dunbar C., Liu J., Nakamura R., Young N.S., and Barrett A.J. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Annals of Internal Medicine 137 3 (2002) 156-163
41. Murphy M.F., Wallington T.B., Kelsey P., Boulton F., Bruce M., Cohen H., Duguid J., Knowles S.M., Poole G., and Williamson L.M. Guidelines for the clinical use of red cell transfusions. British Journal of Haematology 113 1 (2001) 24-31
42. Musto P., Lanza F., Balleari E., Grossi A., Falcone A., Sanpaolo G., Bodenizza C., Scalzulli P.R., La Sala A., Campioni D., Ghio R., Cascavilla N., and Carella A.M. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. British Journal of Haematology 128 2 (2005) 204-209
43. National Comprehensive Cancer Network (NCCN) Myelodysplastic Panel Members, 2005. NCCN Clinical Practice Guidelines in Oncology - v.2.2006: myelodysplastic syndromes. 〈www.nccn.rog/professionals/physician_gls/PDF/mds.pdf〉. Accessed: 12-30-2005.
44. Oncology Nursing Society, 2005. Future frontiers in the treatment of myelodysplastic syndromes. 〈http://www.ons.org/publications/journals/pdfs/spotlight19.pdf〉. Accessed: 12-29-2005.
45. Raza A., Meyer P., Dutt D., Zorat F., Lisak L., Nascimben F., du Randt M., Kaspar C., Goldberg C., Loew J., Dar S., Gezer S., Venugopal P., and Zeldis J. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 98 4 (2001) 958-965
46. ®-Pharmacy's Fundamental Reference, 2006. Montvale, NJ, Thomson PDR.
47. Richardson P., and Anderson K. Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma. Journal of Clinical Oncology 22 16 (2004) 3212-3214
48. Ruter B., Wijermans P.W., and Lubbert M. Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2′-deoxycytidine retreatment in high-risk myelodysplasia patients. Cancer 106 8 (2006) 1744-1750
49. Saunthararajah Y., Nakamura R., Wesley R., Wang Q.J., and Barrett A.J. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 102 8 (2003) 3025-3027
50. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., Stone R.M., Nelson D., Powell B.L., DeCastro C.M., Ellerton J., Larson R.A., Schiffer C.A., and Holland J.F. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. Journal of Clinical Oncology 20 10 (2002) 2429-2440
51. Strupp C., Germing U., Aivado M., Misgeld E., Haas R., and Gattermann N. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 16 1 (2002) 1-6
52. The Sickle Cell Information Center, 2005. Management of Sickle Cell Disease (NIH publication no. 02-2117). Transfusion, iron overload, and chelation (chapter 25). 〈http://www.scinfo.org/nihnewchap25.htm〉. Accessed: 12-30-2005.
53. Thomas M.L. Quality of life and psychosocial adjustment in patients with myelodysplastic syndromes. Leukemia Research 22 (1998) S41-S47
54. Vardiman J.W., Harris N.L., and Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 7 (2002) 2292-2302
55. Wagner L., and Lacey M.D. The hidden costs of cancer care: an overview with implications and referral resources for oncology nurses. Clinical Journal of Oncology Nursing 8 3 (2004) 279-287
56. Wijermans P., Lübbert M., Verhoef G., Bosly A., Ravoet C., Andre M., and Ferrant A. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. Journal of Clinical Oncology 18 5 (2000) 956-962
57. Yee K.W., Jabbour E., Kantarjian H.M., and Giles F.J. Clinical experience with decitabine in North American patients with myelodysplastic syndrome. Annals of Hematology 84 suppl 13 (2005) 18-24